Camptothecin Antibody-Drug Conjugates for Selective Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cleavable drug conjugates suffer from non-selective uptake into both cancer and normal cells due to hydrophobic linker-drugs, leading to limited therapeutic efficacy and adverse reactions, with existing efforts to reduce hydrophobicity being insufficient.
Innovation Solution
Development of novel camptothecin derivative-based antibody-drug conjugates with cleavable linkers and cell-binding groups, designed to selectively target cancer cells by using specific conditions for drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cleavable drug conjugates are used, then the binding specificity of antibodies is combined with the potency of chemotherapeutic agents, but non-selective uptake into both cancer and normal cells occurs due to hydrophobicity of linker-drugs
Solution Approach 1:
The patent modifies the chemical parameters of the linker-drug conjugate by introducing a cleavable linker with specific chemical bonds (e.g., disulfide bonds, hydrazone bonds) that can be selectively broken under specific conditions (reducing environment, acidic pH) inside cancer cells, changing the stability and solubility parameters to achieve selective drug release only in target cells
Solution Approach 2:
The cleavable linker acts as an intermediary component between the antibody and the chemotherapeutic agent, serving as a conditional connection that remains intact during circulation but breaks down under specific intracellular conditions, thereby mediating selective drug delivery to cancer cells while protecting normal cells
2Reliability
If hydrophobic linker-drugs are used to maintain potency, then therapeutic efficacy is enhanced, but non-selective uptake into normal cells increases
Solution Approach 1:
The drug conjugate is segmented into distinct functional modules: an antibody component for target recognition, a cleavable linker for conditional connection, and a potent chemotherapeutic agent for therapeutic effect. This segmentation allows each component to perform its specific function while the cleavable linker provides the selective release mechanism that prevents premature drug activation in normal cells
3Reliability
If cleavable linkers are introduced to enable selective drug release, then therapeutic selectivity is improved, but device complexity increases
Solution Approach 1:
The invention extracts and isolates the cleavable linker as a separate, well-defined chemical component with specific cleavage mechanisms (disulfide, hydrazone, peptide bonds). By taking out this specific functional element and optimizing it independently, the overall system achieves selective drug release without requiring complex multi-component systems, as the cleavable linker alone provides the necessary selectivity mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances therapeutic efficacy by accurately delivering drugs to cancer cells while minimizing harm to healthy cells, reducing adverse reactions, and improving treatment outcomes for cancers and autoimmune diseases.
Implementation Method 1
LC is a cleavage group
Data Source
AI summary
The present disclosure is directed toward drugs or toxins; drug conjugates comprising said drugs or toxins and a cleavable linker; and conjugates comprising said drugs or toxins, cleavable linkers, and cell-binding groups. The present disclosure also relates to methods of treating cancers, autoimmune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.